



GLAND PHARMA LIMITED

August 28, 2025

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Proceedings of the 47th Annual General Meeting of the Company

We hereby notify you that the 47th Annual General Meeting (AGM) of the Company was held on Thursday, 28th August 2025 at 11:00 A.M. through Video Conferencing / Other Audio-Visual Means (OAVM).

In compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Speech & Presentation by Mr. Srinivas Sadu - Executive Chairman, enclosed as Annexure A
2. Speech & Presentation by Mr. Shyamakant Giri – CEO, enclosed as Annexure B
3. Proceedings of the AGM, enclosed as Annexure C

This is for your information and records.

Yours truly,

For Gland Pharma Limited

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Encl: Annexures A, B & C



Annexure A

Forty-Seventh Annual General Meeting Thursday, 28th August 2025 Address by Mr. Srinivas Sadu – Executive Chairman

Good morning, ladies and gentlemen. On behalf of the board of directors of Gland Pharma Limited, I cordially invite each one of you to the 47th Annual General Meeting of the Company. This meeting is being held through video conferencing and other audio-visual mode. We comply with the regulatory requirements of Securities and Exchange Board of India.

The Company has taken all possible steps to ensure that the shareholders are provided with an opportunity to participate at the Annual General Meeting and also to vote. We are very much pleased to have your virtual presence here together with us today.

Presentation by the Executive Chairman

Good morning again, ladies and gentlemen. It is with a profound sense of honour and responsibility that I stand before you today, having stepped into the role of Executive Chairman. The trust you have placed in me to lead this remarkable organization, which is built on a foundation of integrity and an extraordinary legacy, is both humbling and inspiring.

My journey with Gland Pharma began in 2000, and over these past two decades, I have had the distinct privilege of witnessing firsthand our ascent. We began as a formidable challenger and have grown into one of the leading players in the highly competitive injectables market.

Our trajectory has been guided by a clear vision, a strategic alignment with the evolving needs of global healthcare, and an absolute commitment to quality and regulatory compliance.

Our strengths have not only enabled us to navigate a dynamic and often challenging industry landscape, but they have also forged an organization that is uniquely poised for even greater things.

Together, we will continue to build on this powerful foundation, delivering exceptional value and making a lasting, meaningful impact on global health.

Navigating Change and Accelerating Opportunities

The past year has marked an important inflection point in the global economy. As the world has begun to recalibrate, new growth avenues have emerged. The International Monetary Fund's latest outlook, while reflecting a cautious optimism, credits disciplined policymaking, stronger cross-border collaboration, and innovation as key drivers of this stabilization. However, we must remain vigilant, as challenges still persist.

The reintroduction of tariffs by the US administration, for instance, has added a layer of complexity for Indian pharmaceutical firms with a significant footprint in the US market. These



developments necessitate a strategic agility and a firm commitment to cost discipline to ensure our continued growth and competitiveness on the global stage.

Amidst these shifts, the Indian pharmaceutical sector continues to demonstrate remarkable strength, and Gland Pharma remains firmly positioned within it. The fundamentals of our industry, and indeed our business, remain robust.

This is supported by powerful structural demand drivers and, critically, our proven execution capability. The global injectable market, in particular, is an area of significant opportunity.

We anticipate it will witness sustained expansion, driven by the rising global burden of chronic diseases, a greater adoption of patient-centric drug delivery formats, and the continuous advancements in complex biologics. While we will always be mindful of regulatory compliance and pricing pressures, the overall opportunity is significant and growing.

Our Journey of resilient Growth

I am delighted to share our performance for the fiscal year 2024–25. Gland Pharma delivered a consolidated revenue of ₹56,165 million and an EBITDA of ₹12,689 million, with a margin of 23%. This performance is particularly noteworthy as it marks an improvement in our EBITDA margin year-on-year, a clear reflection of the adaptability and strength of our business model in navigating external uncertainties.

Our Core Base Business, excluding Cenexi, was the engine of our growth, generating ₹41,248 million in revenue. This strong performance was fueled by a robust pipeline of new product launches, continued strategic investments in complex injectables and advanced delivery platforms, and our highly productive in-house R&D program.

Our base business also demonstrated exceptional operational strength, with EBITDA margins rising to 35%, up from 34% in the previous year. This significant margin expansion was the direct result of a favorable product mix, disciplined cost management across the board, and improved efficiency throughout our value chain.

In Cenexi, which contributed ₹14,916 million in revenue during the year, we acknowledge that its performance was below our initial expectations. However, we have already laid the groundwork for a clear and decisive turnaround which started demonstrating results in Q1'26. Our focus is strategically shifting away from lower-value, high-volume offerings towards higher-value segments. This deliberate transition is expected to increase the realizable revenue per unit and drive long-term profitability for this important acquisition.

On the regulatory front, we strengthened our global compliance profile in a way that is foundational to our business. I am pleased to report that our facilities in Dundigal and Pashamylaram received Establishment Inspection Reports (EIRs) from the US FDA. This is not just a procedural milestone; it is an affirmation of our unwavering commitment to quality, safety, and compliance—values that are essential to sustaining trust with regulators, customers, and patients around the globe.



A Foundation of Purpose: Our Commitment to ESG

Our commitment to Environmental, Social, and Governance (ESG) is not merely a corporate initiative; it is a holistic philosophy that is deeply embedded in every facet of our operations.

- **Environmental:** We are accelerating our shift toward cleaner energy. We have made significant solar infrastructure investments at our manufacturing sites, which are measurably reducing our carbon footprint. Our water conservation initiatives, driven by technology upgrades and real-time monitoring, reflect our responsible stewardship of natural resources.
- **Social:** On the social front, our efforts are focused on creating a tangible, positive impact within the communities we serve. Our projects span from enhancing school infrastructure and providing support for orphanages to implementing various rural welfare programs. Our dedicated CSR Committee provides strategic oversight to ensure that these programs are not only aligned with our core values but also create meaningful and lasting outcomes.
- **Governance:** We maintain the highest standards of governance, which underpins our entire operation. This ensures that we operate with transparency, accountability, and integrity, building a culture of compliance, trust, and safety that is vital for long-term success.

The Six Pillars of our Future Growth

As we look to the future, we do so with confidence, clarity, and tremendous momentum. I am particularly excited about the new chapter we are beginning with the new CEO taking over the growth strategy. This marks a new era of renewed energy and a strong focus on execution. Our strategic priorities are centered around scaling our core operations, deepening our innovation pipeline, and driving sustainable value creation.

Specifically, our vision for the future is built upon six key strategic dimensions:

- 1. Expanding our base business:** We will achieve this through a relentless focus on operational excellence, strategic market expansion, and the development of differentiated delivery platforms that meet patient needs.
- 2. Enhancing our manufacturing capabilities:** Our focus will be on scalability, ensuring the highest levels of quality, and maintaining impeccable global compliance standards to serve markets around the world.
- 3. Accelerating innovation:** We will do this through a robust pipeline of complex injectables and the strategic scale-up of our biologics CDMO platform, positioning us at the forefront of pharmaceutical innovation.
- 4. Exploring strategic M&A:** We will proactively seek out opportunities for mergers and acquisitions to access new technologies, diversify our portfolio, and enter untapped markets that offer significant growth potential.



5. Embedding ESG: Our commitment to ESG is not a checkbox. We will embed it in every aspect of our value chain—from minimizing our environmental impact to fostering social upliftment and ensuring strong governance.

6. Upholding a culture of compliance: We will continue to champion a culture of compliance, trust, and safety across all our operations, ensuring that we deliver with integrity to patients and partners worldwide.

A shared Future and Heartfelt Thanks

The future of Gland Pharma is bright. It is fueled by the dedication of our people, the strength of our collaborations, and the enduring trust of you, our valued stakeholders.

Together, we are poised to redefine excellence, deliver enduring value, and shape a healthier future for all.

Thank you!!!



Gland Pharma Limited


47th Annual General Meeting

Srinivas Sadu
Executive Chairman

28th August 2025

Building on our Strengths - Preparing for the Future

Charting Our Course Together: A Legacy of Excellence



Navigating a Shifting Global Landscape



Global Economic Landscape

- The past year marked an important inflection point in the global economy.
- The International Monetary Fund's latest outlook credits disciplined policymaking, stronger cross-border collaboration, and innovation as key drivers of this stabilization.



Navigating Challenges

- Challenges still persist, such as the reintroduction of tariffs by the US administration.
- These developments necessitate strategic agility and a firm commitment to cost discipline.



Our Strong Positioning

- The Indian pharmaceutical sector continues to demonstrate remarkable strength, with Gland Pharma firmly positioned within it.
- The global injectable market is an area of significant opportunity and is anticipated to witness sustained expansion.

Our Journey of Resilient Growth

Consolidated P&L

Particulars	FY25	FY24	YoY
Revenue from operations	56,165	56,647	-1%
Other Income	2,136	1,702	25%
Total Income	58,301	58,349	0%
Gross Profit⁽¹⁾	35,261	34,916	1%
Gross Profit Margin(%)	63%	62%	
EBITDA⁽²⁾	12,689	13,331	-5%
EBITDA Margin(%) ⁽³⁾	23%	24%	
PBT	10,627	11,325	-6%
PBT Margin(%)	19%	20%	
PAT	6,985	7,725	-10%
PAT Margin(%) ⁽⁴⁾	12%	14%	

Base Business (Gland) P&L

Particulars	FY25	FY24	YoY
Revenue from operations	41,248	41,769	-1%
Other Income	2,078	1,671	24%
Total Income	43,327	43,441	0%
Gross Profit⁽¹⁾	23,943	23,567	2%
Gross Profit Margin(%)	58%	56%	
EBITDA⁽²⁾	14,451	14,142	2%
EBITDA Margin(%) ⁽³⁾	35%	34%	
PBT	14,607	14,109	4%
PBT Margin(%)	35%	34%	
PAT	10,868	10,456	4%
PAT Margin(%) ⁽⁴⁾	26%	25%	

Cenexi

Particulars	FY25		FY24 *		YoY
	€ Mn.	₹ Mn.	€ Mn.	₹ Mn.	
Revenue from operations	164	14,916	166	14,878	0.3%
Gross Profit	125	11,318	126	11,349	-0.3%
% margin	76%	76%	76%	76%	
EBITDA	(19)	(1,761)	(9)	(812)	
% margin	-12%	-12%	-5%	-5%	

Financial Performance:

- For FY25, Gland Pharma delivered a consolidated revenue of **₹56,165 million** and an EBITDA of **₹12,689 million**, with a margin of **23%**.
- This performance marks a year-on-year improvement in the EBITDA margin.

Business Segment Performance:

- The **Core Base Business**, excluding Cenexi, was the engine of growth, generating **₹41,248 million** in revenue.
- In **Cenexi**, which contributed **₹14,916 million** in revenue, its performance was below initial expectations, but a clear turnaround has begun.

Regulatory Highlights:


- Our facilities in Dundigal and Pashamylaram received Establishment Inspection Reports (EIRs) from the US FDA.
- This is an affirmation of the company's unwavering commitment to quality, safety, and compliance.

A Foundation of Purpose: Our Commitment to ESG

“

A commitment to Environmental, Social, and Governance (ESG) is a holistic philosophy deeply embedded in every facet of operations.

”



The Six Pillars of Our Future Growth



A Shared Future and Heartfelt Thanks



- The future of Gland Pharma is bright, fueled by the dedication of our people, the strength of our collaborations, and the enduring trust of you, our valued stakeholders.



- We are poised to redefine excellence, deliver enduring value, and shape a healthier future for all.



- Thank you to stakeholders for being a part of this remarkable journey.



***Building on our Strengths
Preparing for the Future***



Annexure B

Forty-Seventh Annual General Meeting

Thursday, 28th August 2025

Address by Mr. Shyamakant Giri – Chief Executive Officer

Good morning to our esteemed shareholders, respected Board members, and valued stakeholders. It is with great pride and a strong sense of responsibility that I am addressing you today as the new Chief Executive Officer of Gland Pharma. I thank you for the trust you have placed in me to lead this exceptional organization toward unprecedented success.

I extend my sincere appreciation to our Chairman, Mr. Sadu, for his insightful and inspiring address. His emphasis on our "clear vision" and "unwavering commitment to quality and compliance" are not just guiding principles, they are non-negotiable standards that will drive our relentless pursuit of excellence. It is a privilege to build upon the robust foundation you have established.

Presentation by the Chief Executive Officer

We have adeptly navigated a dynamic global landscape and seized opportunities that have fortified our operational stability and profitability. Importantly, we have significantly accelerated our momentum toward sustainable, long-term growth. This unwavering commitment showcases the resilience of our business and our disciplined execution, which will propel us to new heights in the future.

Expanding Our Market Presence

As the Chairman highlighted, the global injectable market is expanding, and we are strategically positioned to capitalize on this opportunity.

Our U.S. operations, a primary growth engine, have achieved consolidated revenue of ₹30,387 million. This reflects the strategic decisions we have made to enhance our therapeutic presence in the world's largest pharmaceutical market. This year, we successfully launched 31 new molecules, reinforcing our leadership and addressing critical patient needs.

In Europe, our operations are progressing steadily, contributing a revenue of ₹10,470 million. The robust 28% year-on-year growth in our other core markets demonstrates the effectiveness of our tailored, market-specific strategies.

Revenue from Rest of the World (ROW) markets reached ₹10,800 million, while our India operations provided a notable revenue of ₹2,487 million. These outcomes affirm our sharp focus on identifying and capitalizing on emerging opportunities that will drive sustainable, long-term growth across all regions.



Building on Innovation

Our chairman rightly emphasized that accelerating innovation and enhancing our manufacturing capabilities are critical strategic imperatives.

We are making significant strides in these areas. Our complex product strategy is gaining prominent traction with a focused portfolio of 19 complex products—nine of which have already been filed as of March 2025. Six have been launched, and we anticipate regulatory approvals for three more shortly. Together, these products have a market opportunity estimated at around USD 6.5 billion, presenting substantial potential for growth and enhanced shareholder value.

Our commitment to innovation is evident in our strategic partnerships. We are advancing 15 formulations, including seven 505(b)(2) and eight ANDAs, with commercialization set to begin in the next few years. Additionally, our Ready-to-Use (RTU) infusion bag segment is gaining significant momentum, with 14 registered RTU products aimed at the U.S. market, valued at approximately USD 530 million. This positions us strongly to meet the increasing demand for patient-friendly, differentiated delivery platforms.

Our R&D investments totalled ₹1,922 million this year, reflecting a robust 4.7% of our base business revenues. This investment has driven the filing of 24 new ANDAs and secured 32 product approvals. Our cumulative ANDA filings now stand at 371, with 318 approvals and 53 pending.

As the Chairman articulated, scaling up our biologics CDMO platform is a key priority for our future. The biologics sector is poised for high growth, and we are positioning ourselves as a formidable player. Through strategic collaborations and targeted infrastructure investments, we are advancing our standing in this critical area.

Our Strategic Roadmap

Looking ahead, I fully align with the six strategic dimensions outlined by our Chairman. Our roadmap for sustainable growth and enhanced shareholder returns is anchored in these priorities:

- 1. Base business expansion:** We are focused on deepening market penetration, successfully launching new products, and increasing our market share within existing therapeutic areas.
- 2. Augmenting capabilities:** We are committed to expand our manufacturing footprint to meet the surging global demand.
- 3. Foray into Biologics CDMO:** We are aggressively scaling our CDMO capabilities in the biologics sector to leverage this high-growth opportunity.
- 4. R&D and portfolio expansion:** We will accelerate these efforts to drive innovation and broaden our product portfolio through both internal development and synergistic partnerships.
- 5. Strategic acquisitions and integration:** We remain committed to the Cenexi turnaround strategy to optimize operations and drive growth.



6. Upholding a culture of compliance: We will continue to champion a culture of compliance, trust, and safety across all our operations.

A vision of confidence

As we look ahead, we do so with confidence in our strategy, conviction in our capabilities, and clarity in our purpose. Our diversified business, our future-focused investments, and our ability to adapt and innovate, position us well to continue delivering value for patients, partners, and you, our esteemed shareholders.

Thank you for your unwavering support and belief in our ambitious vision for Gland Pharma. Together, we will achieve remarkable success.

Thank you!!!



Gland Pharma Limited

47th Annual General Meeting

Shyamakant Giri
Chief Executive Officer

28th August 2025

Building on our Strengths - Preparing for the Future


Expanding Our Market Presence

Consolidated Market-Wise Performance

Particulars	FY25	FY24	Y-o-Y
USA	30,387	30,375	0%
Europe	10,470	10,648	-2%
Canada, Australia & New Zealand (Other Core Markets)	2,021	1,575	28%
India	2,487	2,810	-11%
Rest of the world	10,800	11,239	-4%
TOTAL	56,165	56,647	-1%

Base Business (Gland) Market-Wise Performance

Particulars	FY25	FY24	Y-o-Y
USA	29,766	29,780	0%
Europe	1,555	1,556	0%
Canada, Australia & New Zealand (Other Core Markets)	1,374	1,100	25%
India	2,487	2,810	-11%
Rest of the world	6,066	6,524	-7%
TOTAL	41,248	41,769	-1%



US Market:

- US market, a key growth driver, delivered a consolidated revenue of **₹30,387 million**.
- The portfolio was expanded with the launch of **31** new molecules, strengthening leadership and reinforcing our position as a trusted partner.

Other Core Markets:

- European operations showed steady progress, contributing a revenue of **₹10,470 million**.
- Other core markets grew by an impressive 28% year-on-year, reflecting the success of tailored, market-specific strategies.

Emerging Markets:

- Revenue from Rest of the World (ROW) markets reached **₹10,800 million**.
- The India business contributed a revenue of **₹2,487 million**, underscoring a deliberate focus on capturing emerging opportunities.

Extensive Portfolio of Complex Products

Present in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings

Delivery Systems:

- Liquid vials
- Lyophilized vials
- Pre-filled syringes
- Ampoules
- Bags
- Drops
- Pens
- Cartridges

Therapeutic Areas:


- Anti-diabetic
- Anti-infectives
- Anti-malarial
- Anti-neoplastic (Oncology)
- Blood-related
- Cardiac
- Gastro-intestinal
- Hormones
- Neurological and Central Nervous System
- Ophthalmics and Otologicals
- Pain, neuro-muscular blocking agents & analgesics
- Respiratory
- Vitamins, minerals & nutrients

R&D & Regulatory Capabilities

- Dedicated R&D facility at Hyderabad, with on-site support at each manufacturing location, boasts a team of over ~257 professionals, including PhDs, pharmacy post-graduates, and chemists.
- Scale of expertise enables rapid and efficient development and supports global regulatory filings.
- Capabilities span a broad range of pharmaceutical research, with growing expertise in injectables, allowing new products to market quickly and efficiently.

Regulatory Track Record

Total 371 ANDAs ⁽¹⁾



Total 1,748 Product Registrations Globally ⁽¹⁾



Complex Product Strategy:

- A focused portfolio of 19 complex products is gaining substantial traction.
- Nine products have been filed as of March 2025, with six already launched.

Co-development:

- Jointly advancing 15 formulations, including seven 505(b)(2) and eight ANDAs.
- Commercialization is expected to begin in the next couple of years.

Differentiated Delivery Platforms:

- The Ready-to-Use (RTU) infusion bag segment continues to gain momentum.
- We now have 14 registered RTU products for the US market, with a total estimated value of approximately USD 530 million.

R&D Investments:

- R&D investments totaled ₹1,922 million during the year, representing 4.7% of our base business revenues.
- This investment fueled the filing of 24 new ANDAs and the receipt of 32 product approvals.
- Cumulative ANDA filings now stand at 371, with 318 approvals and 53 pending.

Our Strategic Roadmap



Base business expansion

- Deeper market penetration, new product launches, and increasing market share.



Augmenting capabilities

- Expanding our manufacturing footprint to meet growing global demand.



Foray into Biologics CDMO

- The biologics sector is a high-growth area, and we are strategically positioning ourselves to be a major player through collaborations and targeted infrastructure investments.



R&D and portfolio expansion

- Accelerating efforts to drive innovation and broaden the product portfolio.



Strategic acquisitions and integration

- Committed to the Cenexi turnaround strategy to optimize operations and drive growth.



Upholding a culture of compliance

- Championing a culture of compliance, trust, and safety across all operations.

A Vision of Confidence



- Looking ahead with confidence in our strategy, conviction in our capabilities, and clarity in our purpose.



- Our diversified business, future-focused investments, and ability to adapt and innovate position us well to continue delivering value.



- Committed to delivering value for patients, partners, and you, our esteemed shareholders.



- To our dedicated team, our valued partners, and you, our esteemed shareholders, thank you for being a part of this journey



***Building on our Strengths
Preparing for the Future***



Annexure C

Summary of the proceedings of the 47th Annual General Meeting (AGM) of the members of Gland Pharma Limited ('the Company') held on Thursday, 28 August 2025 at 11.00 A.M. (IST) through video conferencing (VC) facility/other audio-visual means (OAVM).

Directors Present through VC:

1.	Mr. Srinivas Sadu	Executive Chairman (participation from Corporate Office, Hyderabad)
2.	Mr. Satyanarayana Murthy Chavali	Independent Director (participation from Hyderabad)
3.	Ms. Naina Lal Kidwai	Independent Director (participation from New Delhi)
4.	Mr. Essaji Goolam Vahanvati	Independent Director (participation from Mumbai)
5.	Mr. Udo J Vetter	Independent Director (participation from Montenegro, Europe)
6.	Dr. Jia Ai Zhang	Director (participation from Shanghai)
7.	Mr. Wenjie Zhang	Director (participation from Shanghai)
8.	Ms. Wei Huang	Director (participation from Shanghai)

In attendance through VC, participated from Hyderabad, India:

1.	Mr. Shyamakant Giri	Chief Executive Officer
2.	Mr. Ravi Shekhar Mitra	Chief Financial Officer
3.	Mr. Sampath Kumar Pallerlamudi	Company Secretary & Compliance Officer

Other representatives through VC:

1. Mr. Sathya Pramod Koushik, Authorised representative of Ms. Monisha Parikh, Partner of M/s. Deloitte Haskins & Sells, Statutory Auditors, participated from Hyderabad, India
2. Ms. D Soumya, Secretarial Auditor, M/s RVR & Associates, Practising Company Secretaries, participated from Hyderabad, India
3. Mr. G. Ravikanth, Scrutinizer, M/s G. Ravikanth & Associates, Practising Company Secretaries, participated from Hyderabad, India

Members Present:

51 members (including speakers) attended the 47th Annual General Meeting through VC/OAVM.

Mr. Srinivas Sadu, Executive Chairman occupied the Chair and welcomed the members and corporate representatives to the Meeting. The quorum being present, the Meeting was called to order. The Chairman then introduced the Directors to the shareholders.



Thereafter, Mr. Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer informed the members that the Meeting is being conducted through video conference and webcast as per the provisions of the Companies Act, 2013 and various circulars issued by the MCA and SEBI.

He further stated that the Board's Report, Auditors' Report, Financial Statements for the FY 2024-25 and other reports along with Notice of the Meeting have already been circulated to the members who have already registered their e-mail ID at their registered e-mail ID and to the members who have not registered their e-mail ID, a letter containing a weblink and QR Code for accessing the Notice of 47th AGM and the Annual Report for the financial year 2024-25 has been sent. He further informed that since there were no qualifications, observations, comments or remarks in the Statutory Auditor's report and the Secretarial Auditor's report for the year ended 31st March 2025; the reports of the Auditors were taken as read.

He also informed that the statutory documents, registers and reports as required to be maintained under the Companies Act, 2013 and all other documents referred to in the Notice which are required to be placed at the AGM for inspection by the members are open for inspection electronically.

The members were informed that the Company had provided the facility to cast their vote electronically, on all resolutions set forth in the notice of the 47th AGM through remote e-voting provided by MUFG Intime India Private Limited (Formerly known as Linkintime India Private Limited). The remote e-voting facility was open from 9.00 AM (IST) on Monday, August 25, 2025 and was closed at 5.00 PM on Wednesday, August 27, 2025.

The Company Secretary further informed the members that those members who attended the AGM and had not cast their votes through remote e-voting prior to the Meeting were provided an opportunity to cast their votes during the AGM through the e-voting facility provided by MUFG Intime.

Thereafter, the Company Secretary invited the Chairman to address the shareholders and deliver his speech.

The Executive Chairman, Mr. Srinivas Sadu apprised the shareholders as below:

"It is with a profound sense of honour and responsibility that I stand before you today, having stepped into the role of Executive Chairman. The trust you have placed in me to lead this remarkable organization, which is built on a foundation of integrity and an extraordinary legacy, is both humbling and inspiring.

My journey with Gland Pharma began in 2000, and over these past two decades, I have had the distinct privilege of witnessing firsthand our ascent. We began as a formidable challenger and have grown into one of the leading players in the highly competitive injectables market.

Our trajectory has been guided by a clear vision, a strategic alignment with the evolving needs of global healthcare, and an absolute commitment to quality and regulatory compliance.

Our strengths have not only enabled us to navigate a dynamic and often challenging industry landscape, but they have also forged an organization that is uniquely poised for even greater things.



Together, we will continue to build on this powerful foundation, delivering exceptional value and making a lasting, meaningful impact on global health.”

Thereafter, he presented to the shareholders a brief overview of the journey of the Company and future business prospects.

Mr. Srinivas Sadu has made a brief presentation on navigating change and Accelerating Opportunities; Journey of resilient growth; Commitment to ESG and apprised about the Six Pillars of our future growth, etc.

Post the presentation, Executive Chairman handed over the proceedings to the Chief Executive Officer to address the shareholders of the Company.

Mr. Shyamakant Giri, Chief Executive Officer has apprised the shareholders as below:

“It is with great pride and a strong sense of responsibility that I am addressing you today as the new Chief Executive Officer of Gland Pharma. I thank you for the trust you have placed in me to lead this exceptional organization toward unprecedented success.

I extend my sincere appreciation to our Chairman, Mr. Sadu, for his insightful and inspiring address. His emphasis on our "clear vision" and "unwavering commitment to quality and compliance" are not just guiding principles, they are non-negotiable standards that will drive our relentless pursuit of excellence. It is a privilege to build upon the robust foundation you have established.

We have adeptly navigated a dynamic global landscape and seized opportunities that have fortified our operational stability and profitability. Importantly, we have significantly accelerated our momentum toward sustainable, long-term growth. This unwavering commitment showcases the resilience of our business and our disciplined execution, which will propel us to new heights in the future.”

Thereafter, he presented to the shareholders a brief overview of the business and outlook.

Mr. Shyamakant Giri has made a brief presentation on Expanding our Market presence, Building on Innovation, our strategic roadmap and apprised on the vision of confidence, etc.

With the permission of the Chairman, the Company Secretary explained to the shareholders the resolutions put forth for approval. He stated that since the Meeting was held through VC and the resolutions provided in the Notice were being put to vote through e-voting, there would not be any proposing and seconding of the resolutions.

The resolutions put up for shareholder’s approval were as under:

Ordinary Business:

1. To receive, consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2025 including the Audited Balance Sheet as at 31st March, 2025; the Statement of Profit and Loss, Statement of changes in Equity and the Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Reports of the Board of Directors and Auditors thereon.



2. To receive, consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2025 including the Audited Consolidated Balance Sheet as at 31st March, 2025; the Consolidated Statement of Profit and Loss, Consolidated Statement of changes in Equity and the Consolidated Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Report of the Auditors thereon.
3. To declare the final dividend on equity shares for the financial year ended 31st March 2025.
4. To reappoint Dr. Jia Ai Zhang as a Director, liable to retire by rotation and being eligible offers himself for reappointment.
5. To reappoint Mr. Srinivas Sadu as a Director, liable to retire by rotation and being eligible offers himself for reappointment.

Special Business:

6. To approve the appointment of Secretarial Auditors of the Company.
7. To re-appoint Mr. Essaji Goolam Vahanvati (DIN: 00157299) as an Independent Director of the Company and consider commission on profits as remuneration to him.

Resolutions no. 1 to 6 were proposed as Ordinary resolutions and Resolution no. 7 was proposed as Special Resolution.

Thereafter, queries were invited from the shareholders. The queries posed by the shareholders were suitably responded by Mr. Srinivas Sadu, Executive Chairman, Mr. Shyamkant Giri, CEO and Mr. Ravi Shekhar Mitra, CFO.

Thereafter, the Chairman announced for voting to be taken electronically (e-voting) and requested Mr. G. Ravikanth, the scrutinizer for the orderly conduct of the e-voting.

The Chairman, authorized the Company Secretary to receive the scrutinizer's report and to announce the combined e-voting results, intimate the stock exchanges and place the same on the website of the Company.

The Chairman thanked the shareholders for attending the 47th AGM of the Company and declared the Meeting as concluded at 12:48 P.M. (including 30 minutes time allowed for e-voting during AGM)

The scrutinizer's report was received, and all the resolutions as set out in the Notice of the 47th AGM were declared as approved with requisite majority.

For Gland Pharma Limited

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer